What are the drug indications of Vonoprazan Fumarate ?

Vonoprazan Fumarate is a potassium-competitive acid blocker that is the first of its kind. It received market approval in Japan in February 2015.

P-CABs, such as vonoprazan, are a novel and heterogeneous class of medicines that completely block the potassium binding site of gastric H+/K+ ATPase, potentially circumventing the limits of proton-pump inhibitors.

Vonoprazan fumarate is used to treat gastroduodenal ulcers (including some drug-induced peptic ulcers) and reflux esophagitis, and it can be used in conjunction with antibiotics to eradicate Helicobacter pylori.

Vonoprazan-amoxicillin co-packaged combinations and vonoprazan-amoxicillin and clarithromycin co-packaged combinations were approved for medicinal use in the United States in May 2022.

One comment

  1. There are a few drug indications for Vonoprazan Fumarate. It is generally used to treat advanced stage cancer, but there are a few limited indications for it. It is also being used to treat a rare form of leukemia.

    It is not recommended for pregnant women or people who are breastfeeding.

    Alternative Names: Takeda (Originator); TAK-438; TAKECAB; Vocinti; VONOPION®; Vonoprazan fumarate; VONOSAP®; VOQUEZNA DUAL PAK; VOQUEZNA TRIPLE PAK

    Check out more:


Leave a Reply

Your email address will not be published. Required fields are marked *